Though the role of the loss of certain ChrY genes has been partially characterized in BCs (e.g., KDM5D loss conferring an aggressive tumor phenotype with high responsiveness to immunotherapy) the exact dynamics by which LOY contributes to a tumor’s phenotype is less clear. Here, KDM5D is linked to neoplasm.